These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 211004)

  • 21. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
    Williams G; Anderson JV; Williams SJ; Bloom SR
    Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
    Gorden P; Comi RJ; Maton PN; Go VL
    Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin, basic and clinical studies. A review.
    Schally AV; Meyers CA
    Mater Med Pol; 1980; 12(1-2):28-32. PubMed ID: 6120265
    [No Abstract]   [Full Text] [Related]  

  • 24. Somatostatin: physiological and clinical significance.
    Guillemin R; Gerich JE
    Annu Rev Med; 1976; 27():379-88. PubMed ID: 779605
    [No Abstract]   [Full Text] [Related]  

  • 25. Neuroendocrine islet cell tumour producing gastrin and ACTH in a patient with calcifying chronic pancreatitis.
    Allison MC; Renfrew CC; Webb WJ; Chappell ME; Pounder RE
    Gut; 1985 Apr; 26(4):426-8. PubMed ID: 2984096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of somatostatin on gastrin, insulin and glucagon secretion in two patients with Zollinger-Ellison syndrome.
    Fallucca F; Delle Fave G; Giangrande L; Del Balzo P; De Magistris L; Carratù R
    J Endocrinol Invest; 1981; 4(4):451-3. PubMed ID: 6120969
    [No Abstract]   [Full Text] [Related]  

  • 27. [Zollinger-Ellison syndrome and metastatic insulinoma; its response to streptozotocin].
    Agular-Parada E; Rivadeneyra-Hinojosa J; Guzman-Patraca C; Salas-Montero J; Escalante-Herrera A
    Arch Invest Med (Mex); 1977; 8(1):31-8. PubMed ID: 192163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatostatin inhibition of insulin and gastrin hypersecretion in pancreatic islet-cell carcinoma.
    Curnow RT; Carey RM; Taylor A; Johanson A; Murad F
    N Engl J Med; 1975 Jun; 292(26):1385-6. PubMed ID: 166308
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of the effect of levodopa and somatostatin on the plasma levels of growth hormone, insulin, glucagon and prolactin in acromegaly.
    Dunn PJ; Donald RA; Espiner EA
    Clin Endocrinol (Oxf); 1976 Mar; 5(2):167-74. PubMed ID: 1269163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Endocrine (secreting and apparently inert) tumors of the pancreas].
    Bougha P
    J Ont Dent Assoc; 1971 May; 48(5):853-63. PubMed ID: 4325897
    [No Abstract]   [Full Text] [Related]  

  • 31. Somatostatin: a review of its effects especially in human beings.
    Hansen AP; Lundbaek K
    Diabete Metab; 1976 Dec; 2(4):203-18. PubMed ID: 190058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure of oral bromocriptine to affect hypergastrinemia in two patients with the Zollinger-Ellison syndrome.
    Child DF; Laing I; Ganguli PC
    J Endocrinol Invest; 1978 Oct; 1(4):351-3. PubMed ID: 229152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term infusion of growth hormone release inhibiting hormone in acromegaly: effects on pituitary and pancreatic hormones.
    Besser GM; Mortimer CH; McNeilly AS; Thorner MO; Batistoni GA; Bloom SR; Kastrup KW; Hanssen KF; Hall R; Coy DH; Kastin AJ; Schally AV
    Br Med J; 1974 Dec; 4(5945):622-7. PubMed ID: 4374289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pituitary effects of somatostatin.
    Hall R; Snow M; Scanlon M; Mora B; Gomez-Pan A
    Metabolism; 1978 Sep; 27(9 Suppl 1):1257-62. PubMed ID: 210355
    [No Abstract]   [Full Text] [Related]  

  • 35. Suppression and stimulation mechanisms controlling glucagon secretion in a case of islet-cell tumor producing glucagon, insulin, and gastrin.
    Tiengo A; Fedele D; Marchiori E; Nosadini R; Muggeo M
    Diabetes; 1976 May; 25(5):408-12. PubMed ID: 5326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone-producing tumours of the pancreas.
    Giddings AE
    Practitioner; 1975 Jun; 214(1284):795-800. PubMed ID: 167363
    [No Abstract]   [Full Text] [Related]  

  • 37. Pneumocystis carinii pneumonia complicating somatostatin therapy of Cushing's syndrome in a patient with metastatic pancreatic islet cell carcinoma and Zollinger-Ellison syndrome.
    McQuillen DP; Schroy PC; Hesketh PJ; Sugar AM
    Am J Gastroenterol; 1991 Apr; 86(4):512-4. PubMed ID: 1672788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rebound hypergastrinemia after cessation of a somatostatin analogue (SMS 201-995) in malignant gastrinoma.
    Buck M; Kvols LK; O'Dorisio TM
    Am J Med; 1987 May; 82(5B):92-5. PubMed ID: 2884883
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical use of the somatostatin analog SMS 201-995 in endocrinology.
    Cozzi R; Liuzzi A; Dallabonzana D; Oppizzi G; Orlandi P; De Palo C; Petroncini MM; Piolini M; Chiodini PG
    J Endocrinol Invest; 1988 Nov; 11(10):737-40. PubMed ID: 2852695
    [No Abstract]   [Full Text] [Related]  

  • 40. Hypothalamic hormone interaction in acromegaly.
    Gomez-Pan A; Tunbridge WM; Duns A; Hall R; Besser GM; Coy DH; Schally AV; Kastin AJ
    Clin Endocrinol (Oxf); 1975 Sep; 4(5):455-60. PubMed ID: 170027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.